Verdiva Bio
Drug Discovery · Biotechnology
Overview
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
Key facts
These are the key facts about Verdiva Bio on Alion as of Nov 13, 2026. The latest round is Series A of $410M, announced in 2025.
- Employees
- 200+Alion company profile, an estimated range
- Total raised
- $410MSum of 1 equity round Alion knows
- Latest round
- Series A · $410M · Jan 11, 2025Press report · pulse2.com
Funding and backers
Total raised
$410M
1 round on record
Latest round
$410M
Series A · Jan 2025 · 22 mo ago
Team
201-500
employees, estimated range
Backers
2
RA Capital Management, OrbiMed
The money's age
Due for its next round
22 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 11, 2025
Raised a round Series A $410M · Pulse 2.0
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Jan 2025 | $410M | — | Pulse 2.0 |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
PAhR Therapeutics is a clinical-stage biotech company advancing innovative therapies to treat pulmonary arterial hypertension (PAH) through…
Terrestrial is transforming the delivery of next-generation therapies, starting with GLP-1. Terrestrial.
Sparrow Pharmaceuticals is an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of…
MitoRx is developing new treatments to restore healthy mitochondrial metabolism in patients living with high-risk obesity.
Kailera is a late clinical-stage biotechnology company advancing a diversified pipeline of GLP-1 therapies to provide options for people…
Refoxy Pharmaceuticals GmbH is a pre-clinical biotech company developing FOXO3-targeting therapies to restore cellular balance and treat…
Financials
Total raised
$410M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2025 | $410M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
RA Capital ManagementVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Verdiva Bio Initiates Phase 1 Study of VRB-103, a Selective Oral Amylin Peptide Analog With Weekly Dosing Potential
Read more
Report
Verdiva Bio to Present Preclinical Data on Investigational Obesity Drug Candidates at the American Diabetes Association 86th Scientific Sessions
Read more
Report
Verdiva Bio Announces Completion of Enrollment for EVOLVE-2 Phase 2b Study of VRB-101, a Potential Once-Weekly Oral GLP-1 Peptide Analog in Individuals with Obesity
LONDON & SAN FRANCISCO, February 24, 2026--Verdiva Bio announces completion of enrollment for EVOLVE-2 Phase 2b study of VRB-101
Read more
Report
Verdiva Bio Announces Completion of Enrollment for EVOLVE-2 Phase 2b Study of VRB-101, a Potential Once-Weekly Oral GLP-1 Peptide Analog in Individuals with Obesity
Read more
Report
Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions
Read more
Report
Verdiva Bio: Cardiometabolic Company Raises Over $410 Million (Series A)
Verdiva Bio announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. And the company is advancing a portfolio of next-generation oral and injectable trea
Read more
Report
How to cite this page
Alion, "Verdiva Bio: key facts", as of Nov 13, 2026. https://alion.io/company/world-3783097
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0